Ventriculo-arterial (un)coupling in septic shock: Impact of current and upcoming hemodynamic drugs

Sepsis is an archetype of distributive shock and combines different levels of alterations in preload, afterload, and often cardiac contractility. The use of hemodynamic drugs has evolved over the past few years, along with the invasive and non-invasive tools used to measure these components in real time. However, none of them is impeccable, which is why the mortality of septic shock remains too high. The concept of ventriculo-arterial coupling (VAC) allows for the integration of these three fundamental macroscopic hemodynamic components. In this mini review, we discuss the knowledge, tools, and limitations of VAC measurement, along with the evidence supporting ventriculo-arterial uncoupling in septic shock. Finally, the impact of recommended hemodynamic drugs and molecules on VAC is detailed.

Introduction

The hemodynamic management of septic shock is an evolving challenge guided by recommendations updated regularly. According to the 2021 Surviving Sepsis Campaign (SSC) guidelines, with a target for a mean arterial pressure (MAP) of 65 mmHg or greater, norepinephrine, dobutamine, vasopressin, and possibly angiotensin II are the recommended medications after volume optimization (1). The majority of these drugs act on the two major components of hemodynamic homeostasis, i.e., the vascular network and the cardiac pump. However, emerging data (i.e., goal-directed therapies) support the use of additional or alternative targets to MAP and/or cardiac output (CO) with more adaptive and efficient resuscitation guidance (2).

Ventriculo-arterial coupling (VAC) is the net result of complex and constant interactions between the cardiac pump and its downstream vascular network (3). The objective of VAC is to consider the function of the heart with its afterload (the downstream arterial tree) as a whole and not separately and ideally to quantify the overall efficiency of the system. This allows us to go beyond the known limits of the simple measurement of the left ventricular ejection fraction (LVEF) or peripheral vascular resistance and to consider the adequacy of one in relation to the other. Thus, VAC provides a more physiological and integrative understanding of the cardiovascular function and may be a key element in the characterization and even the management of shock. For more than half a century, as for other hemodynamic measurement devices, tools for assessing VAC have evolved from invasive to potentially more affordable non-invasive approaches. Nevertheless, VAC remains difficult to apprehend in a practical routine. Therefore, to better understand this essential concept, this mini review aims to briefly address the principles of VAC and outline the alterations during septic shock and the impact of current and experimental circulatory drugs. Faced with the general concept of VAC and using a systematic search for the PubMed bibliographic database in VAC published works using the following keywords, “ventriculo-arterial coupling”; “uncoupling”; “vascular elastance”; “end-systolic elastance”; “hemodynamic drugs”; and “septic shock,” this narrative mini review focuses on the interaction between the left ventricle and the systemic arterial circulation during septic shock. No specific consideration for fluid resuscitation and right ventricle function is displayed.

General principles of ventriculo-arterial coupling: a core determinant of cardiovascular performance

Although the heart and systemic vascular network have different intrinsic properties, both aim to provide adequate organ perfusion (through the generation of an outflow volume with a given level of outflow pressure). There is little sense in studying one without taking into consideration the condition of the other. Thus, the VAC concept was first proposed in 1984 as a method to evaluate the mechanical efficiency of the cardiovascular system and the interaction between cardiac performance and vascular function (4). For a complete review, see Antonini-Canterin et al. (5).

Ventricular properties

Ventricular performance can be characterized by its end-systolic elastance (Ees), which reflects the ability of the ventricle to eject a stroke volume (SV) through the variation of the end-systolic pressure. In brief, it reflects the adaptability of the ventricle to the variation of afterload. From a physiological point of view, it is determined by the slope of the line passing through the point of the end of systole and by the theoretical point of zero volume (V0) on a pressure/volume loop and may be summarized by $Ees=\frac{Pes}{(Ves-V0)}$, where Pes and Ves are end-systolic pressure and volume, respectively. The accurate determination of Ees is difficult to assess, but its value can be estimated by the single-beat determination method developed by Chen et al. (6).

Arterial properties

Properties of the vascular system are defined by vascular elastance (Ea), reflecting the resistance and compliance of the main arteries. Ea may be determined from the slope that joins end-diastolic volume and pressure and may be summarized as Ea = Pes/SV (7).

VAC estimation

The Ea/Ees ratio is called the VAC index, reflecting the systolic performance of the left ventricle in front of the arterial compliance. Several publications estimated that the optimal VAC values are comprised of between 0.6 and 1.2 (3) or 0.5 and 1.3 (8). Beyond 1.3 implies ventriculo-arterial uncoupling and thus unbalance between reduced arterial compliance and ventricular inefficiency, which is appealing to therapeutic intervention (9).

Despite several proposed non-invasive approaches to evaluate VAC, only the modified single-beat method developed by Chen et al. (6) has been validated against the invasive measurement of Ees. This method utilizes the echocardiographic measures of LVEF, Doppler-derived SV [using the formula: SV = velocity–time interval (VTI, cm) × area (cm²), with VTI obtained using pulsed wave Doppler in the aortic wave during systole in a five-chamber view, and area = π × (diameter of the aortic annulus)/2, where the diameter of the aortic annulus is measured in the parasternal long-axis view during systole)], the estimated normalized ventricular elastance at the onset of ejection [End(est)], and the pre-ejection time (PET = time interval from the beginning of the QRS complex to the opening of the aortic valve) to left ventricle ejection time (LVET = time interval from the opening of the aortic valve to the closure of the aortic valve) ratio (tNd) (Figure 1), coupled with non-invasive systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements. The equations used are (6):

$Ees=(DBP\text{–}[End(est)\times SBP\times 0.9])/End(est)\times SV$

FIGURE 1

Figure 1. Schematic representation of echocardiographic measurements of PET, LVET, and SV. LVET, left ventricle ejection time; PET, pre-ejection time; SV, stroke volume; VTI, velocity–time interval.

$Ea=\frac{(SBP\times 0.9)}{SV}$

with

$\begin{array}{rl}End(est)=& 0.0275\text{–}0.165\times LVEF+0,3656\\ & \times (DBP/(SBP\times 0,9))+0,515\times End(avg)\end{array}$

$End(avg)=0.35695-7.2266\times tNd+74.249\times tN{d}^2-307.39\times tN{d}^3+684.54\times tN{d}^4\text{–}856.92\times tN{d}^5+571.95\times tN{d}^6-159.1\times tN{d}^7$

$tNd=PET/LVET$

The iElastance^© application is a simplified method to evaluate the VAC value by Chen et al.'s method without performing the calculations by hand (10).

Sepsis-induced ventriculo-arterial uncoupling

A traditional hemodynamic perspective of acute sepsis characterizes this syndrome as a pattern of blood volume redistribution resulting in low blood pressure associated with variable fluid and vasopressor responsiveness (10, 11). However, on a case-by-case basis, at least 10% of patients do have subnormal circulatory parameters at admission, and up to 40% exhibit sepsis-associated cardiac dysfunction (12–14) (Figure 2).

FIGURE 2

Figure 2. Early (acute) sepsis hemodynamics and ventriculo-arterial uncoupling on admission. From top to bottom: (A) The main components of sepsis-induced hemodynamic instability are first pictured out: *Relative percentages of patients: blood volume, 35%–45% N to↑ and 55%–65%↓ or ↓↓; global heart function, 75%–80% N to↑ and 20%–25% ↓ or ↓↓; systemic resistance and blood pressure, 10%–15% N to↑ and 85%–90% ↓ or ↓↓, as reported in ref. (13–21). (B) This comes down into counter-parted alterations in P/V loop parameters overall leading to ventriculo-arterial (VA) uncoupling which is characterized by variable unmatched changes of arterial elastance -Ea- and/or end-systolic left ventricular elastance—Ees-, moving up the ratio above 1.36, as defined by Guarracino et al. (22, 23). Prevalence of VA uncoupling has been observed in more than one- to more than three-quarters of early septic shock patients, depending on the study. **Relative percentages of patients with VA uncoupling: 25%–85%, as reported in ref. (12, 22–26). Potential moves of Ea (pink) and Ees (black) slopes are exemplified in dashed lines. (C) A priority with VAC integration into a novel early goal-directed therapy would be to recouple the heart and circulation toward optimal efficiency with Ea/Ees in-between a “normal range” estimated in healthy humans ***, as reported in ref (3). N, normal; Ea, arterial elastance; Ees, end-systolic elastance; ESPVR, end-systolic pressure–volume relationship; EDPVR, end-diastolic pressure–volume relationship; PE, potential energy; SW, stroke work; Pes, end-systolic pressure; Ves, end-systolic volume.

VA uncoupling is frequently observed in the early phase of septic shock. In the literature, the prevalence of uncoupling (e.g., defined by Ea/Ees ratio >1.36) in critically ill patients varies from 25% to 85% (16–19) (Figure 2) and is associated with higher mortality (18). Also, a trend of distortion in the Ea/Ees ratio, outcome-related, has been recently observed in a small cohort study (20). Lowering the Ea/Ees ratio between 0.6 and 1.2—a range generally observed in healthy humans—could be a target goal (Figure 2) (3). VA uncoupling can exist despite normal or subnormal blood pressure (16). Hence, sizing shock resuscitation after volume optimization solely to a 65 mmHg MAP level for all patients and regardless of any cardiac function assessment does not seem to be adequate. This could lead to premature use and higher doses of vasopressors and an inappropriate increase in Ea (and afterload) as well as an increase in stroke work, globally reinforcing VA uncoupling. Also, it should be noted that VA uncoupling can be observed in patients with “normal” LVEF, enhancing the necessity of a more accurate circulatory assessment.

Hemodynamic drug impacts on VAC specifically relevant to sepsis

Few drugs are currently available for the circulatory support of septic shock, and one does not fit all. To stretch a point, inotropes enhance Ees, whereas vasopressors specifically increase Ea, but several drugs share both abilities. Some patients do sometimes require more inotropism than vasopressors, because around 40% exhibit sepsis-induced myocardial depression (21). Many of the interventions frequently performed in these patients can directly or indirectly affect the arterial load and ventricular function, making the use of standardized strategies in sepsis difficult (20, 21). Thus, the assessment of VAC is of interest to critically ill patients in selecting correctly the appropriate drug for personalized sepsis resuscitation. In this section, we will discuss the existing literature on VAC and representative circulatory agents that are used or are under evaluation to be used in septic shock.

Norepinephrine

Norepinephrine (NE) is a natural catecholamine that exerts a dose-dependent vasoconstrictive effect by its agonism on α-adrenergic receptors present throughout the vasculature (27). NE has also an inotropic effect, even if to a lesser extent, on β-adrenergic receptors (24). NE targets not only the arterial tree but also the venous blood reservoir, leading to the recruitment of an initially unconstrained blood volume toward a so-called constrained volume (27, 28). Moreover, NE also rises blood pressure of the Valsalva sinus and induces β₂-mediated vasodilation of coronary arteries, overall normalizing coronary blood flow and contributing to an improved cardiac function (29). Finally, NE exerts a direct inotropic effect on the myocardium through both α₁ and β₁ stimulation (30). Thus, circulatory effects of NE in sepsis can contribute to the three main areas of hemodynamic homeostasis: i.e., pre- and afterload and cardiac inotropism. Unfortunately, the beneficial effects and responsiveness of NE also depend on the course of sepsis, timing of administration, actual vascular resistance, and the prior cardiac status of the patient. Specifically, a preexisting heart failure, where any increase in afterload may impair ventricular ejection, is potentially problematic for NE use. This suggests the exploration of VAC as a reliable parameter to explore the global circulatory effects of NE in sepsis, even though very few studies have explored this issue with somewhat contradictory observations. Zhou et al. (31) showed that, in 34 septic shock patients, NE infusion tends to normalize VAC by elevating Ees to a higher magnitude than Ea. Moreover, patients with Ea/Ees ratio close to 1.0 are more sensitive to increase their SV with NE infusion. In contrast, Guarracino et al. observed that, in a prospective cohort study, NE infusion of septic shock patients enhanced Ea with minimal effects on Ees, leading to a worsening of VA uncoupling and loss of left ventricular efficiency (25). In this study, nearly half of the patients did not respond to NE, whereas responding patients presented with less elevated Ea/Ees values. Thus, quite often, rather than a consequence of NE infusion, VA uncoupling was a cause of NE inefficiency. This evidence-based finding argues for guiding appropriate circulatory treatment during shock states by monitoring VAC because it may be an indirect marker of myocardial stunning in sepsis. This is reinforced by the validation of the dynamic arterial elastance

$\left(\mathrm{Eadyn}={\displaystyle \frac{\mathrm{pulse}\mathrm{pressure}\mathrm{variation}(\mathrm{PVV})}{\mathrm{stroke}\mathrm{volume}\mathrm{variation}(\mathrm{SVV})}}\right)$

 an indirect marker of VAC, as a predictor of successful NE weaning (22). The higher the Eadyn and left ventricular efficiency, the lower the VAC (23).

Dobutamine

Dobutamine is an old synthetic catecholamine exerting powerful inotropic effects through its agonism on β₁ receptors and is still widely used in circulatory shock (25). The surviving sepsis campaign (SSC) suggests adding dobutamine in cases of shock refractory to NE (1). Dobutamine used in patients with reduced CO and low LVEF in septic shock can contribute to restoring circulation. In this context, when MAP is sustainably low despite NE infusion, the addition of dobutamine resulted in a significant improvement of VAC (23). The latter came from a 35% reduction of the Ea/Ees ratio, mainly because of an increase in Ees with minimal effects on Ea, and a subsequent increase of SV (25). This “recoupling” of the ventricle and aorta may explain the suggested reduction of mortality in septic shock patients treated with dobutamine, as observed in a network meta-analysis (32). From a pathophysiological point of view, dobutamine improves VAC by both improving myocardial inotropism and by reducing afterload through a β₂-mediated vasodilator effect, most notably in NE pre-treated patients in whom arterial resistance is often normal or supranormal. Nevertheless, starting dobutamine infusion in septic shock must be preceded by an echocardiography assessment and preferably after VAC exploration, to avoid potentially harmful administration in patients without cardiac dysfunction. This point may explain the inefficiency or even increased mortality rates with dobutamine use in sepsis, as reported by several meta-analyses and retrospective studies (33, 34). Finally, it should be noted that, because of its positive chronotropic effects, dobutamine could lead to ventriculo-arterial uncoupling. Indeed, excessive, and inappropriate tachycardia could lead to an increase in arterial elastance by increasing the telesystolic pressure (early dicrotic wave).

Levosimendan

Levosimendan is a “new” generation inodilator with different pharmacodynamic properties than catecholamines, since it does not interact with adrenergic receptors (35). Its mechanisms of action involve sensitization of calcium–troponin interactions and activation of potassium channels, both of which allow an increase in inotropism and vasodilation (25). Benefits have been demonstrated with levosimendan infusion in patients with chronic congestive heart failure and may also be beneficial in perioperative cardiac surgery, although these results need to be confirmed (36–40). However, the use of levosimendan in septic shock is highly controversial, as testified by the results obtained by Gordon et al. (41) in a randomized trial of 516 septic shock patients where no benefit was observed and higher rates of supraventricular arrhythmia and issues in weaning from mechanical ventilation were revealed. Nevertheless, in this trial, the studied population was not selected for sepsis myocardial failure, and less than 20% of patients were pretreated with dobutamine in addition to NE, potentially explaining both the lack of a positive impact and the most frequent side effects of levosimendan. Recent meta-analyses are more supportive of the use of levosimendan in septic shock with higher CO and lactate blood level reduction in comparison with dobutamine (26) but without an obvious drop in mortality rates (42). In an animal model of septic shock induced by LPS administration, levosimendan, in contrast to cAMP-dependent inotropes (dobutamine and milrinone), partially restored left ventricular contractility by increasing Ees and improved myocardial relaxation and cardiac filling, without altering vascular properties (Ea not altered by levosimendan administration) (43). Although efficient in rebalancing the Ea/Ees ratio of patients with human ischemic cardiomyopathy, the effect of levosimendan on VAC was unfortunately never directly explored in human septic shock (44). Despite similar effects on VAC as dobutamine can be expected with levosimendan, further studies are warranted to explore this topic.

β-blockers

Unlike the above drugs, β-blockers (BBs) inhibit β1 receptors but may also be of interest during septic shock under specific conditions of circulatory failure. Two recently developed BBs stand out from the others because of their pharmacokinetics and pharmacodynamics, i.e., esmolol and landiolol (45). These two drugs do have powerful selective β1-blocking effects with minimal β2-blocking impact and a short elimination half-life, even more pronounced for landiolol. In septic shock, esmolol and landiolol have been demonstrated to reduce heart rate, without impacting MAP in a majority of patients (46, 47). This does not oppose the positive effects of catecholamines and inodilators discussed above but further supports the need for VAC assessment of patient selection. Different profiles of septic patients can explain whether tachycardia is adaptive or maladaptive and whether blocking or stimulating the adrenergic system is required. In a cohort of 45 patients, Morelli et al. (48) observed that a reduction of heart rate using esmolol resulted in a decrease of Ea with a concomitant increase of SV. Indeed, tachycardia induces an acceleration of the pulse wave reflection (dicrotic wave), generating an additional pressure in telesystole (and no longer in protodiastole). Thus, in the case of maladaptive tachycardia, the end-systolic pressure is increased, as is Ea (=ESP/SV). These patients presented a preserved LVEF above 50%, suggesting that the beneficial effects address patients without sepsis-induced myocardial depression. Although these results are of great interest, particularly because of the clinical improvement with reduced NE requirements, they also need to be confirmed by further analyses as to the direct effects on VAC (49). Indeed, the authors focused on Ea without correctly evaluating Ees, whereas an altered myocardial function by β-receptor blockade cannot be ruled out (50). In a post hoc analysis and to overcome this limitation, these authors suggested the use of the systolic–dicrotic notch pressure difference as an indirect tool for evaluating VAC and representative of the efficiency of myocardial contraction (systolic pressure) in opposition to a given afterload (dicrotic notch pressure). In this context, low values of systolic–dicrotic notch pressure difference were related to VA uncoupling and could predict at baseline the ability of β-blockers to improve cardiac efficiency with a heart rate reduction, discriminating adaptive from maladaptive tachycardia (48). Although attractive and simple, such an approach needs to be confirmed, notably because of the number of limitations regarding the reliability of arterial waveforms in distal locations of the heart and with some settings (51). In summary, BBs may be of interest in septic shock patients when a maladaptive tachycardia impedes left ventricular filling and limits ventricular ejection. In that event, lowering heart rate recouples the ventricle with the arterial tree by maximizing ventricle performance and with little effect on arterial compliance (notably when using β₁ selective antagonists, such as esmolol and landiolol). A still unresolved genuine challenge is the fine-tuning selection of candidate patients.

Other drugs and molecules

Arginine vasopressin (AVP) and apelins (APL) belong to a family of neuropeptides with pleiotropic, often counter-regulatory, cardiovascular or related effects (52). AVP has a somewhat recognized added value with specific catecholamine-sparing vasoconstrictive effects in septic shock (1, 53), without a direct effect on the heart identified. From a physiological point of view, AVP has a vagal- and/or sympathetic-independent cardiodepressant effect (54). More specifically, AVP drops the left ventricular ESPVR slope, shifting it to the right (55). Pathophysiologically, AVP-specific V1 receptor (V1aR) expression is increased in failing hearts, but this is related to an impaired cardiac function independently of any effect on the vascular system (56). AVP-specific V2 receptors (V2aR) in the heart can have a positive inotropic effect but needs gene transfer overexpression (57). APL are still molecules in development, but in the preclinical stage, they improve cardiac function, diuresis, and the cardiorenal axis, counteracting the AVP activities (58–60). However, the inotrope ability of APL is still a matter of debate (despite several demonstrations in vivo and in isolated hearts ex vivo). The essential absolute gain of CO in response to APL-13 isoform is clearly linked to SV improvement without significant chronotropic effect but with an attributable contribution of the underlying degree of total peripheral resistance. VAC, as well as ventricular mechanical efficiency, are improved by more than 40% with APL-13 infusion in experimental ischemic failing hearts with an induced increase of the Ea/Ees ratio (61). APL-13 also clearly improves the left ventricular P/V relationship and reduces Ea in small and large animal models of septic shock (58–60). Essentially studied at the preclinical level, APL have been also assayed in humans (both healthy volunteers and patients with pulmonary arterial hypertension and heart failure). In recent years, several pharmaceutical companies have worked on APL receptor agonists such as PEGylated, N-linked hydroxypyridine-based APL, and AMG-986 agonists. The latter was a first-in-man trial using an orally delivered molecule that was recently released, showing a potentially interesting rise of SV in chronic heart failure patients (62–64).

Angiotensin II has been recently added as a recommended third-line rescue vasopressor for refractory septic shock in the SSC guidelines (1). This is a powerful vasoconstrictive agent, devoid of any direct cardiac effect, increasing ventricular stroke work and load. As to VAC, angiotensin II is an improbable candidate to restore Ea/Ees balance in septic patients with an uncoupling profile as it is more likely to increase Ea. This additionally argues for selecting patients on the potential of benefiting or not from this drug.

Conclusion

In conclusion, VAC is a valuable tool for understanding the interaction between the myocardial contractile function and the load opposed by the arterial circulation. Although many data are encouraging, the benefit of such an approach to in-hospital outcomes should be confirmed in the future. Additional proof of applicability and optimal targets are needed to consider VAC at the bedside in complex hemodynamic conditions, such as septic shock, where tachycardia and pharmacologic increase in vascular resistance contributes to ventriculo-arterial uncoupling in associated but overlooked myocardial injury. This would support the decision-making strategies of intensivists in today’s world of individualized medicine.

Author contributions

All authors contributed to the review writing and editing. All authors contributed to the article and approved the submitted version.

Conflict of interest

EB received fees for expertise from Amomed Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest..

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. (2021) 47:1181–247. doi: 10.1007/s00134-021-06506-y

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Zhou X, Zhang Y, Pan J, et al. Optimizing left ventricular-arterial coupling during the initial resuscitation in septic shock—a pilot prospective randomized study. BMC Anesthesiol. (2022) 22:31. doi: 10.1186/s12871-021-01553-w

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Monge García MI, Santos A. Understanding ventriculo-arterial coupling. Ann Transl Med. (2020) 8:795. doi: 10.21037/atm.2020.04.10

CrossRef Full Text | Google Scholar

4. Sunagawa K, Sagawa K, Maughan WL. Ventricular interaction with the loading system. Ann Biomed Eng. (1984) 12:163–89. doi: 10.1007/BF02584229

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Antonini-Canterin F, Poli S, Vriz O, Pavan D, Bello VD, Nicolosi GL. The ventricular-arterial coupling: from basic pathophysiology to clinical application in the echocardiography laboratory. J Cardiovasc Echogr. (2013) 23:91––5. doi: 10.4103/2211-4122.127408

CrossRef Full Text | Google Scholar

6. Chen CH, Fetics B, Nevo E, et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. (2001) 38:2028–34. doi: 10.1016/S0735-1097(01)01651-5

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Sagawa K, Maughan L, Suga H, Sunagawa K. Cardiac contraction and the pressure-volume relationships. New York: Oxford University Press, (1988).

8. Chantler PD, Lakatta EG. Arterial-ventricular coupling with aging and disease. Front Physiol. (2012) 3:90. doi: 10.3389/fphys.2012.00090

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Kass DA, Kelly RP. Ventriculo-arterial coupling: concepts, assumptions, and applications. Ann Biomed Eng. (1992) 20:41–62. doi: 10.1007/BF02368505

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Trambaiolo P, Figliuzzi I, Salvati M, et al. Ventriculo-arterial coupling in the intensive cardiac care unit: a non-invasive prognostic parameter. Int J Cardiol. (2022) 348:85–9. doi: 10.1016/j.ijcard.2021.12.026

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Groeneveld AB, Bronsveld W, Thijs LG. Hemodynamic determinants of mortality in human septic shock. Surgery. (1986) 99:140–53.3511560

PubMed Abstract | Google Scholar

12. Groeneveld AB, Nauta JJ, Thijs LG. Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med. (1988) 14:141–7. doi: 10.1007/BF00257468

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Lee YI, Smith RL, Gartshteyn Y, Kwon S, Caraher EJ, Nolan A. Predictors of acute hemodynamic decompensation in early sepsis: an observational study. J Clin Med Res. (2016) 8:575–81. doi: 10.14740/jocmr2597w

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Hemodynamic instability in sepsis: bedside assessment by Doppler echocardiography. Am J Respir Crit Care Med. (2003) 168:1270–6. doi: 10.1164/rccm.200306-816CC

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. (2008) 36:1701–6. doi: 10.1097/CCM.0b013e318174db05

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Nasu M, Sato R, Takahashi K, Nakaizumi T, Maruyama A, Ueda S. The chronological demographics of ventricular-arterial decoupling in patients with sepsis and septic shock: a prospective observational study. J Intensive Care Med. (2022):8850666221120219. doi: 10.1177/08850666221120219

CrossRef Full Text | Google Scholar

17. Guarracino F, Ferro B, Morelli A, Bertini P, Baldassarri R, Pinsky MR. Ventriculoarterial decoupling in human septic shock. Crit Care. (2014) 18:R80. doi: 10.1186/cc13842

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Guarracino F, Bertini P, Pinsky MR. Cardiovascular determinants of resuscitation from sepsis and septic shock. Crit Care. (2019) 23:118. doi: 10.1186/s13054-019-2414-9

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Yan J, Zhou X, Hu B, et al. Prognostic value of left ventricular-arterial coupling in elderly patients with septic shock. J Crit Care. (2017) 42:289–93. doi: 10.1016/j.jcrc.2017.08.017

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Foulon P, De Backer D. The hemodynamic effects of norepinephrine: far more than an increase in blood pressure!. Ann Transl Med. (2018) 6:S25. doi: 10.21037/atm.2018.09.27

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. (2018) 72:173–82. doi: 10.1016/j.jacc.2018.04.051

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Guinot P-G, Bernard E, Levrard M, Dupont H, Lorne E. Dynamic arterial elastance predicts mean arterial pressure decrease associated with decreasing norepinephrine dosage in septic shock. Crit Care. (2015) 19:14. doi: 10.1186/s13054-014-0732-5

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Monge García MI, Jian Z, Hatib F, Settels JJ, Cecconi M, Pinsky MR. Dynamic arterial elastance as a ventriculo-arterial coupling index: an experimental animal study. Front Physiol. (2020) 11:284. doi: 10.3389/fphys.2020.00284

CrossRef Full Text | Google Scholar

24. Motiejunaite J, Amar L, Vidal-Petiot E. Adrenergic receptors and cardiovascular effects of catecholamines. Ann Endocrinol. (2021) 82:193–7. doi: 10.1016/j.ando.2020.03.012

CrossRef Full Text | Google Scholar

25. Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol. (2014) 63:2069–78. doi: 10.1016/j.jacc.2014.01.016

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Liu D-H, Ning Y-L, Lei Y-Y, et al. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis. Sci Rep. (2021) 11:20333. doi: 10.1038/s41598-021-99716-9

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Monnet X, Jabot J, Maizel J, Richard C, Teboul J-L. Norepinephrine increases cardiac preload and reduces preload dependency assessed by passive leg raising in septic shock patients. Crit Care Med. (2011) 39:689–94. doi: 10.1097/CCM.0b013e318206d2a3

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Persichini R, Silva S, Teboul J-L, et al. Effects of norepinephrine on mean systemic pressure and venous return in human septic shock. Crit Care Med. (2012) 40:3146–53. doi: 10.1097/CCM.0b013e318260c6c3

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Sun D, Huang A, Mital S, et al. Norepinephrine elicits beta2-receptor-mediated dilation of isolated human coronary arterioles. Circulation. (2002) 106:550–5. doi: 10.1161/01.CIR.0000023896.70583.9F

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Skomedal T, Aass H, Osnes JB. Both alpha 1- and beta-adrenoceptor stimulation determine the time course of the inotropic effect of noradrenaline in rabbit heart. Pharmacol Toxicol. (1990) 67:172–7. doi: 10.1111/j.1600-0773.1990.tb00806.x

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Zhou X, Pan J, Wang Y, Wang H, Xu Z, Zhuo W. Left ventricular-arterial coupling as a predictor of stroke volume response to norepinephrine in septic shock—a prospective cohort study. BMC Anesthesiol. (2021) 21:56. doi: 10.1186/s12871-021-01276-y

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Belletti A, Benedetto U, Biondi-Zoccai G, et al. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. J Crit Care. (2017) 37:91–8. doi: 10.1016/j.jcrc.2016.08.010

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Sato R, Ariyoshi N, Hasegawa D, et al. Effects of inotropes on the mortality in patients with septic shock. J Intensive Care Med. (2021) 36:211–9. doi: 10.1177/0885066619892218

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Zhu Y, Yin H, Zhang R, Ye X, Wei J. The effect of dobutamine in sepsis: a propensity score matched analysis. BMC Infect Dis. (2021) 21:1151. doi: 10.1186/s12879-021-06852-8

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Cholley B, Levy B, Fellahi J-L, et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care. (2019) 23:385. doi: 10.1186/s13054-019-2674-4

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Masarone D, Valente F, Verrengia M, et al. Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience. J Cardiovasc Med. (2020) 21:919–21. doi: 10.2459/JCM.0000000000000983

CrossRef Full Text | Google Scholar

37. Cholley B, Caruba T, Grosjean S, et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. J Am Med Assoc. (2017) 318:548–56. doi: 10.1001/jama.2017.9973

CrossRef Full Text | Google Scholar

38. Caruba T, Charles-Nelson A, Alexander JH, et al. Prophylactic levosimendan in patients with low ejection fraction undergoing coronary artery bypass grafting: a pooled analysis of two multicentre randomised controlled trials. Anaesth Crit Care Pain Med. (2022) 41:101107. doi: 10.1016/j.accpm.2022.101107

PubMed Abstract | CrossRef Full Text | Google Scholar

39. van Diepen S, Mehta RH, Leimberger JD, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. (2020) 159:2302–9.e6. doi: 10.1016/j.jtcvs.2019.06.020

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. (2017) 376:2032–42. doi: 10.1056/NEJMoa1616218

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. (2016) 375:1638–48. doi: 10.1056/NEJMoa1609409

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Bhattacharjee S, Soni KD, Maitra S, Baidya DK. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: a meta-analysis of randomized controlled trials. J Clin Anesth. (2017) 39:67–72. doi: 10.1016/j.jclinane.2017.03.011

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Barraud D, Faivre V, Damy T, et al. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med. (2007) 35:1376–82. doi: 10.1097/01.CCM.0000261889.18102.84

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Guarracino F, Cariello C, Danella A, et al. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy. Acta Anaesthesiol Scand. (2007) 51:1217–24. doi: 10.1111/j.1399-6576.2007.01428.x

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C. Comparison of the β-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions. J Pharmacol Exp Ther. (2016) 359:73–81. doi: 10.1124/jpet.116.232884

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. J Am Med Assoc. (2013) 310:1683–91. doi: 10.1001/jama.2013.278477

CrossRef Full Text | Google Scholar

47. Kakihana Y, Nishida O, Taniguchi T, et al. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. (2020) 8:863–72. doi: 10.1016/S2213-2600(20)30037-0

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Morelli A, Romano SM, Sanfilippo F, et al. Systolic-dicrotic notch pressure difference can identify tachycardic patients with septic shock at risk of cardiovascular decompensation following pharmacological heart rate reduction. Br J Anaesth. (2020) 125:1018–24. doi: 10.1016/j.bja.2020.05.058

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Lescroart M, Pequignot B, Kimmoun A, Klein T, Levy B. Beta-blockers in septic shock: what is new? J Intensive Med. (2022) 2:150–5. doi: 10.1016/j.jointm.2022.01.004

PubMed Abstract | CrossRef Full Text | Google Scholar

50. McLean AS, Taccone FS, Vieillard-Baron A. Beta-blockers in septic shock to optimize hemodynamics? No. Intensive Care Med. (2016) 42:1610–2. doi: 10.1007/s00134-016-4407-3

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Giosa L, Busana M, Payen D. Pitfalls in the assessment of ventriculo-arterial coupling from peripheral waveform analysis in septic shock. Comment on Br J Anaesth 2020; 125: 1018-1024. Br J Anaesth. (2021) 126:e101–2. doi: 10.1016/j.bja.2020.12.016

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Azizi M, Iturrioz X, Blanchard A, et al. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol. (2008) 19:1015–24. doi: 10.1681/ASN.2007070816

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. (2008) 358:877–87. doi: 10.1056/NEJMoa067373

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Elliott JM, West MJ, Chalmers J. Effects of vasopressin on heart rate in conscious rabbits. J Cardiovasc Pharmacol. (1985) 7:6–11. doi: 10.1097/00005344-198501000-00002

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Cheng CP, Igarashi Y, Klopfenstein HS, Applegate RJ, Shihabi Z, Little WC. Effect of vasopressin on left ventricular performance. Am J Physiol. (1993) 264:H53–60. doi: 10.1152/ajpheart.1993.264.1.H53

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Zhu W, Tilley DG, Myers VD, Tsai EJ, Feldman AM. Increased vasopressin 1A receptor expression in failing human hearts. J Am Coll Cardiol. (2014) 63:375–6. doi: 10.1016/j.jacc.2013.09.032

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Laugwitz KL, Ungerer M, Schöneberg T, et al. Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes. Circulation. (1999) 99:925–33. doi: 10.1161/01.CIR.99.7.925

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Chen Y, Xu C, Hu J, et al. Diuretic action of apelin-13 mediated by inhibiting cAMP/PKA/sPRR pathway. Front Physiol. (2021) 12:642274. doi: 10.3389/fphys.2021.642274

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Coquerel D, Chagnon F, Sainsily X, et al. ELABELA improves cardio-renal outcome in fatal experimental septic shock. Crit Care Med. (2017) 45:e1139–48. doi: 10.1097/CCM.0000000000002639

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Coquerel D, Lamoureux J, Chagnon F, et al. Apelin-13 in septic shock: effective in supporting hemodynamics in sheep but compromised by enzymatic breakdown in patients. Sci Rep. (2021) 11:22770. doi: 10.1038/s41598-021-02087-4

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Ouyang Q, You T, Guo J, et al. Effects of apelin on left ventricular-arterial coupling and mechanical efficiency in rats with ischemic heart failure. Dis Markers. (2019) 2019:4823156. doi: 10.1155/2019/4823156

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Ason B, Chen Y, Guo Q, et al. Cardiovascular response to small-molecule APJ activation. JCI Insight. (2020) 5:132898. doi: 10.1172/jci.insight.132898

63. Johnson JA, Kim S-H, Jiang J, et al. Discovery of a hydroxypyridinone APJ receptor agonist as a clinical candidate. J Med Chem. (2021) 64:3086–99. doi: 10.1021/acs.jmedchem.0c01878

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Winkle P, Goldsmith S, Koren MJ, et al. A first-in-human study of AMG 986, a novel apelin receptor agonist, in healthy subjects and heart failure patients. Cardiovasc Drugs Ther. (2022). doi: 10.1007/s10557-022-07328-w

PubMed Abstract | CrossRef Full Text | Google Scholar